General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1 — At a Glance
Suven Life Sciences reported revenue of ₹3.57 crore for the quarter, against expenses of ₹136.07 crore. Revenue rose 90.9% from a year earlier, when it was ₹1.87 crore. Operating profit was negative ₹132.50 crore, against negative ₹50.75 crore a year before. Net loss was ₹127.61 crore, against ₹51.52 crore. Earnings per share, the profit or loss carried by each single share, was negative ₹4.83.
None of this is an accident of one quarter. Suven Life Sciences is a clinical-stage biopharmaceutical company, which means it has no medicine on sale. With no commercial molecule there is no product revenue, and research spending has no sales to sit against. The profit and loss account reads the way a lab notebook would under an accounting standard.
Cash and bank balances stood at ₹337.46 crore at March 2026, up from ₹37.73 crore a year earlier. Financing activities brought in ₹756.78 crore during the year to March 2026. The company has received the entire ₹857.64 crore from its preferential warrant issue. Of that sum, ₹409.50 crore has been used.
Fifteen molecules sit in the development and clinical pipeline. The market capitalisation of the company is ₹9,674 crore. The board announced that SUVN-502 has reached 95% enrolment in its global Phase 3 trial, for agitation in Alzheimer’s dementia.
2 — Introduction
Suven Life Sciences is a biopharmaceutical company headquartered in Hyderabad. It works on drug discovery and development of New Chemical Entities, molecules never used as medicines before. Its field is the central nervous system, meaning the brain and the spinal cord. Its lead molecules address cognitive impairment, including amnesia, dementia and narcolepsy. Alzheimer’s and delirium are on the same list. Clinical development runs through a wholly owned Delaware subsidiary, Suven Neurosciences Inc., set up in 2015.
The present shape of the company dates to 2020. It demerged its contract development and manufacturing business, which made drugs to order for other firms, into Suven Pharmaceuticals Ltd. Shareholders were allotted one Suven Pharmaceuticals share for every share they already held. What stayed behind was discovery and development. What left was the part that sold things. Revenue was ₹625.20 crore in the year to March 2018. It was ₹285.67 crore the year after, and ₹12.62 crore in the year to March 2020.
The last eighteen months have been dominated by raising capital. In May 2025 the board approved 6.40 crore convertible warrants to 23 allottees, and shareholders approved the issue in June 2025. In January 2026 the company allotted 44.78 lakh shares for proceeds of ₹60 crore. In March 2026 it allotted 3.18 crore shares to Jasti Property for ₹425.70 crore. In July 2026 the board allotted a further 1.85 crore shares on warrant conversion, for ₹248.84 crore. At that meeting it also reappointed an independent director and approved a wholly owned subsidiary in Singapore.
June 2026 was busy on the clinical side. A Data Safety Monitoring Board, the independent panel that watches over patient safety in a trial, reviewed the Masupirdine Phase 3 on 4 June. The review was positive and the trial continued unchanged. SUVN-I6107 completed Phase 1 on 16 June. Ropanicant met the primary endpoint of its Phase 2b study on 17 June, and a Phase 3 registrational study is planned.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3 — Business Model: WTF Do They Even Do?
Suven Life Sciences develops molecules for the brain and, so far, sells none of them. That is the category rather than a fault of the company. Fifteen molecules sit in the development and clinical pipeline. Seven are in development phases and eight have reached clinical phases. None has reached commercial stage, and none generates revenue. The model is to spend money for a decade, run trials in people, and find out.
The pipeline as disclosed this quarter is a tour of things the brain does badly. SUVN-502, also called Masupirdine, is in global Phase 3 for agitation in Alzheimer’s dementia, at 95% enrolment. The company targets completed enrolment by the end of September 2026. Last-patient-last-visit, the final trial visit made by the final patient, is set for the first three months of 2027. Results may follow in the three months to June 2027. SUVN-G3031, Samelisant, entered global Phase 3 in April 2026 for excessive daytime sleepiness in narcolepsy. SUVN-911, Ropanicant, completed Phase 2b in major depressive disorder. SUVN-D4010, Usmarapride, has a Phase 2 proof-of-concept design being finalised for cognitive impairment in psychiatric disorder. SUVN-I6107 has finished Phase 1 and is preparing for Phase 2. Five molecules, five different stages, one revenue line of ₹3.57 crore.
The revenue that does arrive comes from drug discovery and development support services sold to global pharmaceutical and biotechnology companies. In the year to March 2022, services were the whole of revenue. India accounted
